Go to the list of all blogs
Nataliia Wilson's Avatar
published in Blogs
Aug 06, 2026
Celsius Holdings (CELH) Stock Faces Headwinds After Q2 Miss and -47% YTD Decline

Celsius Holdings (CELH) Stock Faces Headwinds After Q2 Miss and -47% YTD Decline

Key Takeaways

  • Celsius Holdings shares closed at $29.15 on August 5, 2026, reflecting a decline of approximately 8% over the trailing 30-day period and a steeper drop of roughly 47% year-to-date.
  • Second-quarter 2026 revenue of $817.9 million missed analyst estimates by roughly 6%, while adjusted EPS of $0.36 fell well short of the $0.42–$0.43 consensus, triggering a sharp post-earnings selloff.
  • The flagship CELSIUS brand posted an 11.7% year-over-year revenue decline, pressured by promotional spending, inventory rebalancing, and softness in the club channel.
  • Acquired brands Alani Nu and Rockstar Energy contributed $364.4 million and $66.5 million in quarterly revenue, respectively, underscoring the company's transition into a multi-brand portfolio.
  • Gross margins contracted to 48.1% from 51.5% a year ago, weighed by higher promotional activity and aluminum cost inflation, though management expects margin initiatives to gain traction in the second half of 2026.

Market Snapshot for CELH

Celsius Holdings entered August 2026 under significant pressure. The stock closed at $29.15 on August 5, capping a 30-day period in which shares drifted approximately 8% lower from the $31.70 level recorded in early July. The broader trend has been even more challenging: year-to-date, CELH has shed roughly 47%, sharply underperforming the broader market. Sentiment soured further after the company reported second-quarter results on August 6 that missed both top- and bottom-line expectations, sending shares down an additional 15.9% in post-earnings trading. The stock sits near levels not seen since early 2025, as investors reassess the pace of portfolio integration and the health of the core Celsius brand. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Celsius Holdings' Brand Portfolio and Competitive Position

Celsius Holdings is a functional beverage company operating three distinct energy drink brands: CELSIUS, its flagship zero-sugar fitness-oriented energy drink; Alani Nu, a health-and-wellness brand acquired in April 2025; and Rockstar Energy, added through the acquisition of Big Beverages Contract Manufacturing in August 2025. The company's products are distributed through a broad network that includes PepsiCo's distribution system for Alani Nu, as well as major retailers, club stores, and foodservice outlets across North America and international markets. The combined portfolio held approximately 20.1% dollar share of the U.S. ready-to-drink energy category in the second quarter and contributed roughly 30% of the zero-sugar energy category's dollar growth during the period. With two billion-dollar brands under one roof, Celsius Holdings has emerged as a scaled player in the global energy drink market.

Recent Developments Driving CELH

The most consequential recent event for CELH was the release of second-quarter 2026 financial results on August 6. Revenue grew 10.6% year-over-year to $817.9 million, yet came in meaningfully below the consensus estimate of approximately $885–887 million. Adjusted earnings per share of $0.36 missed forecasts by roughly 14–16%. The flagship CELSIUS brand saw revenue decline 11.7% compared to the same period in 2025, reflecting elevated trade and promotional spending, shipment timing tied to inventory rebalancing, softness in the club channel, and SKU optimization initiatives linked to the integration of Alani Nu and Rockstar. On a more positive note, Alani Nu generated $364.4 million in quarterly sales, buoyed by strong consumer demand, expanded PepsiCo distribution, and a successful limited-time flavor launch. Rockstar Energy contributed $66.5 million. Gross margin contracted by 340 basis points year-over-year to 48.1%, driven by higher promotional activity and commodity cost inflation, particularly in aluminum. International revenue rose 10% to $27.2 million, led by growth in Nordic markets and expansion into the UK, Ireland, France, and Australia. The company also repurchased approximately $100.4 million in shares during the quarter, signaling management confidence in long-term value creation.

2026 Outlook and What Investors Should Watch

Looking ahead, the remainder of 2026 presents several critical monitoring points for Celsius Holdings. The company's ability to stabilize and return the flagship CELSIUS brand to sustainable growth remains central to the investment case, and management commentary around SKU optimization results, distribution productivity, and promotional strategy will be closely scrutinized. Margin recovery initiatives—including freight optimization, raw material alignment, and revenue-growth-management capabilities—are expected to progressively offset commodity headwinds, but the pace of improvement will be a key differentiator. The Alani Nu brand's continued expansion through PepsiCo's distribution network represents a major growth lever, while Rockstar's stabilization trajectory will be watched for signs of contribution margin improvement. On the macro front, aluminum costs, consumer discretionary spending trends, and competitive dynamics within the energy drink category all carry implications for the stock's trajectory. The next quarterly earnings report will serve as an important checkpoint for whether the multi-brand portfolio strategy is delivering on its promise of durable, diversified growth.

Enhancing Research with Tickeron AI Tools

In my ongoing analysis of market signals and trading strategies, I often review Tickeron’s Trending AI Robots page. It curates top-performing AI-powered bots across various time horizons and approaches, providing a streamlined view of where data-driven sentiment is concentrated right now. This helps complement fundamental research with a real-time snapshot of relevant trading signals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CELH

CELH in downward trend: price dove below 50-day moving average on September 08, 2026

CELH moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 34 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CELH as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for CELH turned negative on September 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 35 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

The 10-day moving average for CELH crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CELH's RSI Indicator exited the oversold zone, 21 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELH advanced for three days, in 238 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

CELH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 193 of 220 cases where CELH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CELH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 82 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.907) is normal, around the industry mean (6.793). CELH's P/E Ratio (121.739) is considerably higher than the industry average of (43.051). Projected Growth (PEG Ratio) (0.256) is also within normal values, averaging (3.732). Dividend Yield (0.000) settles around the average of (0.014) among similar stocks. P/S Ratio (2.408) is also within normal values, averaging (2.785).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.

Notable companies

The most notable companies in this group are Coca-Cola Company (NYSE:KO), PepsiCo (NASDAQ:PEP).

Industry description

Non-alcoholic drinks include traces of alcohol or low alcohol content or without alcohol or alcohol removed. Functional Beverages, Carbonated Soft Drinks (CSDs), Sports Drinks, Fruit Beverages, and Bottled Water are some common types of non-alcoholic beverages. The largest segment in this market is soft drinks (think Pepsi and Coke). Many established companies in this space have also been stepping up production of low to zero-calorie varieties in recent years, to cater to a rising number of health-conscious consumers. Coca-Cola Company, Pepsico Inc, Keurig Dr Pepper Inc. and Monster Beverage Corporation are some major non-alcoholic beverage makers.

Market Cap

The average market capitalization across the Beverages: Non-Alcoholic Industry is 45.7B. The market cap for tickers in the group ranges from 1.51K to 375.1B. KO holds the highest valuation in this group at 375.1B. The lowest valued company is NTEI at 1.51K.

High and low price notable news

The average weekly price growth across all stocks in the Beverages: Non-Alcoholic Industry was -0%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -12%. REED experienced the highest price growth at 7%, while BNKK experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Beverages: Non-Alcoholic Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was 19% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 60
Price Growth Rating: 60
SMR Rating: 64
Profit Risk Rating: 76
Seasonality Score: 11 (-100 ... +100)
View a ticker or compare two or three
CELH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in development, marketing of beverages

Industry BeveragesNonAlcoholic

Industry
Beverages Non Alcoholic
Address
2381 Northwest Executive Center Drive
Phone
+1 561 276-2239
Employees
1497
Web
https://www.celsius.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.